Ann: Rexlemestrocel Reduces Heart Attacks/Strokes/CV Death in CHF, page-76

Our friends at AFR have given the market a positive update

33 mins ago – 2.57pm

Mesoblast's rexlemestrocel-L shows reduction in cardiac deaths in trial

William McInnes

Mesoblast's rexlemestrocel-L drug has shown to be effective in a randomised controlled Phase 3 trial, with substantial and durable reductions in heart attacks, strokes, and cardiac deaths after a single dose.

The trial involved 537 patients with chronic heart failure with reduced left ventricular ejection fraction.

The incidence of heart attacks and strokes were reduced by 60 per cent over a median follow-up period of 30 months

"The combination of the three pre-specified outcomes of cardiac death, heart attack or stroke into a single composite outcome - called the three-point Major Adverse Cardiovascular Event (MACE) is a well-established endpoint used by the United States Food and Drug Administration (FDA) to determine cardiovascular risk," said Mesoblast.

"Rexlemestrocel-L significantly reduced this three-point MACE by 30 per cent compared to controls across the population of 537 patients. In the New York Heart Association class II subgroup of 206 patients, rexlemestrocel-L reduced the three-point MACE by 55 per cent compared to controls."